Dcf Advisers, LLC Genmab A/S Transaction History

Dcf Advisers, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $415,500 - $487,200	-10,000 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$33.66 - $40.76 $488,069 - $591,020	-14,500 Reduced 59.18%	10,000 $407,000
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $396,840 - $464,160	12,000 Added 96.0%	24,500 $897,000
Q2 2020 Aug 13, 2020	BUY	$20.05 - $33.89 $250,625 - $423,625	12,500 New	12,500 $424,000

238

48.6M

6.8K

27.6K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.7B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.